Saturday, July 11, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “placebo” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 588
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 588 pipeline programs matching "placebo" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

588 results for “placebo” Back to intelligence hub

Search results

Page 8 of 25
  1. Placebo Spiromax

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule terminated

    1 trial
  2. Placebo cannabis oil. Components: cannabis gr... for Refractory Epilepsy

    Disc Medicine

    Refractory Epilepsy

    phase 3 small molecule active

    1 trial
  3. Placebo capsules for bacterial sexually transmitted…

    The George Institute

    bacterial sexually transmitted infections

    phase 3 small molecule active

    1 trial
  4. Placebo for AMG 145, EVOLOCUMAB

    Amgen

    Adults at high risk of cardiovascular events without prior MI or stroke.

    phase 3 small molecule active

    1 trial
  5. Placebo for AMG 334, Erenumab

    Amgen

    Chronic Migraine

    phase 3 small molecule active

    1 trial
  6. Placebo for AMG 890

    Amgen

    Cardiovascular Disease

    phase 3 small molecule active

    1 trial
  7. Placebo for Adalimumab

    AbbVie

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial
  8. Placebo for Bepirovirsen Solution for Injection 150 mg/mL

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 3 small molecule active

    1 trial
  9. Placebo for Bepirovirsen Solution for Injection 150 mg/mL

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 3 small molecule active

    1 trial
  10. Placebo for Linaclotide

    IRONWOOD PHARMACEUTICALS INC

    Functional Constipation (FC)

    phase 3 small molecule completed

    1 trial
  11. Placebo for MK-7240, tulisokibart

    Merck Sharp and Dohme

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial
  12. Placebo for Mitapivat, MITAPIVAT

    Lacuna Pharma Pty Ltd

    Non–Transfusion-Dependent Alpha- or Beta-Thalassemia

    phase 3 small molecule active

    1 trial
  13. Placebo for Nucresiran, ALN-TTRSC04

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial
  14. Placebo for PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial
  15. Placebo for efgartigimod, ARGX-113

    argenx

    Chronic Idiopathic thrombocytopenic purpura

    phase 3 small molecule active

    1 trial
  16. Placebo for risankizumab, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Crohn's disease

    phase 3 small molecule active

    1 trial
  17. Placebo in combination with Cytarabine Injection

    Moleculin Biotech

    Acute Myeloid Leukaemia (AML)

    phase 3 small molecule active

    1 trial
  18. Placebo injections

    Centocor B.V.

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial
  19. Placebo intramuscular injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Spontaneous Uriticaria

    phase 3 small molecule active

    1 trial
  20. Placebo matching AMX0035, AMX0035

    Lacuna Pharma Pty Ltd

    Progressive Supranuclear Palsy

    phase 3 small molecule active

    1 trial
  21. Placebo matching BI 1291583, BI 1291583

    Boehringer Ingelheim

    Bronchiectasis

    phase 3 small molecule active

    1 trial
  22. Placebo matching DNTH103, DNTH103

    Dianthus Therapeutics, Inc. /DE/

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 3 small molecule active

    1 trial
  23. Placebo matching REGN7508, REGN7508

    Lacuna Pharma Pty Ltd

    Cancer-Associated Thrombosis (CAT).

    phase 3 small molecule active

    1 trial
  24. Placebo matching to garetosmab, Garetosmab

    Lacuna Pharma Pty Ltd

    Fibrodysplasia Ossificans Progressiva

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.